Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades,
the management of non-small cell lung cancer (NSCLC) has undergone a significant …

With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC),
expanding the targeted therapeutic options improved the survival and safety. However …

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver
mutations, which play an important role in carcinogenesis and cancer progression …

Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …

With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the
development of innovative treatment strategies is increasingly vital. This review underscores …

The discovery of oncogenic driver mutations led to the development of targeted therapies
with non-small cell lung cancer (NSCLC) being a paradigm for precision medicine in this …

Oncogenic driver mutations frequently occur in lung cancer and play role in carcinogenesis.
These mutations are usually associated with distinct clinical and histological features and …

Simple Summary The use of novel therapeutic drugs in lung cancer has changed the
paradigm of the diagnosis and treatment of lung cancer. Due to the development of …

Introduction: Driver molecular aberrations, such as EGFR and BRAF mutations, ALK and
ROS1 rearrangements, play an important role in the oncogenesis of non-small-cell lung …

Opinion statement Lung cancer is still responsible for the highest number of cancer deaths
worldwide. Despite this fact, significant progress has been made in the treatment of non …